Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Ascendis Pharma ADR (ASND)

Ascendis Pharma ADR (ASND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,446,837
  • Shares Outstanding, K 60,642
  • Annual Sales, $ 288,670 K
  • Annual Income, $ -521,070 K
  • EBIT $ -382 M
  • EBITDA $ -362 M
  • 60-Month Beta 0.64
  • Price/Sales 26.69
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 49.81% ( +2.92%)
  • Historical Volatility 30.42%
  • IV Percentile 60%
  • IV Rank 23.49%
  • IV High 118.25% on 04/17/24
  • IV Low 28.80% on 09/23/24
  • Put/Call Vol Ratio 4.33
  • Today's Volume 16
  • Volume Avg (30-Day) 268
  • Put/Call OI Ratio 1.46
  • Today's Open Interest 9,014
  • Open Int (30-Day) 9,511

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -1.48
  • Number of Estimates 8
  • High Estimate 0.65
  • Low Estimate -2.12
  • Prior Year -3.12
  • Growth Rate Est. (year over year) +52.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
120.77 +1.70%
on 10/31/24
149.31 -17.74%
on 10/01/24
-26.49 (-17.74%)
since 09/30/24
3-Month
111.09 +10.56%
on 09/12/24
155.53 -21.03%
on 09/20/24
-11.12 (-8.30%)
since 07/30/24
52-Week
86.54 +41.91%
on 11/13/23
161.00 -23.71%
on 02/26/24
+35.42 (+40.53%)
since 10/30/23

Most Recent Stories

More News
3 Oversold Stocks with Big RSI Rebound Potential

Everybody loves finding a bargain or getting a good deal, and it's no different when it comes to stocks. The RSI indicator is a great way to find them.

HUM : 257.83 (-3.19%)
ASND : 122.82 (+0.02%)
BMRN : 65.89 (-1.18%)
ELV : 405.76 (-1.22%)
Why Ascendis Pharma Stock Tumbled by 11% Today

A bottom-line whiff and reduced guidance made the company an outlier for the wrong reasons on Hump Day.

ASND : 122.82 (+0.02%)
Markets Look Ahead to Short Week

Monday Markets are closed for Labour Day Tuesday U.S. Economic Lookahead ...

BIG : 0.4968 (+9.11%)
GWRE : 186.26 (-1.73%)
GCO : 25.62 (-2.73%)
AVGO : 169.77 (-3.89%)
CTLT : 58.60 (-0.63%)
ASND : 122.82 (+0.02%)
DLTR : 64.64 (+2.10%)
ZS : 180.79 (-3.21%)
HPE : 19.49 (-4.18%)
ABM : 53.06 (-1.15%)
DKS : 195.75 (-2.55%)
IOT : 47.79 (-3.16%)
Pendopharm signs exclusive distribution agreement with Ascendis Pharma A/S for TransConâ„¢ PTH in Canada

/CNW/ - Pendopharm, a division of Pharmascience Inc., announced today that it has signed an exclusive distribution agreement with Ascendis Pharma A/S (NASDAQ:...

GM : 50.76 (-2.33%)
ASND : 122.82 (+0.02%)
Ascendant Resources Announces Results of Annual and Special Meeting of Shareholders

/CNW/ - Ascendant Resources Inc. (TSX: ASND) (OTCQB: ASND) ("Ascendant" or the "Company") is pleased to announce the voting results of the Company's 2023...

ASND : 122.82 (+0.02%)
ASND.TO : 0.0500 (-9.09%)
Ascendant Resources Announces Results of Annual and Special Meeting of Shareholders

/PRNewswire/ - Ascendant Resources Inc. (TSX: ASND) (OTCQB: ASND) ("Ascendant" or the "Company") is pleased to announce the voting results of the Company's...

ASND.TO : 0.0500 (-9.09%)
ASND : 122.82 (+0.02%)
Why Shares of Ascendis Pharma Are Climbing Monday

A critical response letter from the FDA means hope remains for the company's hyperthyroidism therapy candidate.

ASND : 122.82 (+0.02%)
ASCENDIS INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Ascendis To Contact Him Directly To Discuss Their Options

/PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ascendis Pharma ("Ascendis" or the...

ASND : 122.82 (+0.02%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ascendis Pharma A/S - ASND

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ascendis Pharma A/S ("Ascendis" or the "Company") (NASDAQ: ASND). Such...

ASND : 122.82 (+0.02%)
ROSEN, A TOP RANKED LAW FIRM, Encourages Ascendis Pharma Investors to Inquire About Securities Class Action Investigation - ASND

/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of...

ASND : 122.82 (+0.02%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Ascendis Pharma A/S is a biopharmaceutical company. The company's product pipeline consist of TransCon Human Growth Hormone, TransCon Treprostinil, TransCon Insulin, TransCon Peptide and TransCon Ranibizumab, which are in different clinical stage, for the treatments of hormone deficiency, endocrinology,...

See More

Key Turning Points

3rd Resistance Point 128.62
2nd Resistance Point 126.64
1st Resistance Point 124.73
Last Price 122.82
1st Support Level 120.84
2nd Support Level 118.86
3rd Support Level 116.95

See More

52-Week High 161.00
Fibonacci 61.8% 132.56
Fibonacci 50% 123.77
Last Price 122.82
Fibonacci 38.2% 114.99
52-Week Low 86.54

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar